Sandbox E20: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
Joel L. Sussman (talk | contribs)
New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you...
 
Joel L. Sussman (talk | contribs)
No edit summary
Line 1: Line 1:
==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='1eve' size='450' side='right' scene='29/2908/1eve_e20_cartoon/3' caption=''>
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
[[Image:E2020_interactins_in_AChE_gorge.jpg|left|250px]]<br />
This is a default text for your page '''Sandbox E20'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
'''3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase'''
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
(see also [[AChE inhibitors and substrates]])
==Background==
Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. '''E2020''', marketed as '''Aricept''', is a member of a large family of N-benzylpiperidine-based [[acetylcholinesterase]] (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of ''Torpedo californica'' AChE (''Tc''AChE) ([[1ea5]]). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range.


== Function ==
{{Clear}}


== Disease ==
==Results==
The X-ray structure of the E2020-''Tc''AChE complex shows that E2020 has a <scene name='1eve/E2020_close_up_with_84_279/13'>unique orientation</scene> along the active-site gorge, extending from the anionic subsite (<scene name='1eve/E2020_close_up_with_84lbld/7'>W84</scene>) of the active site, at the bottom, to the peripheral anionic site (<scene name='1eve/E2020_close_up_with_84_279lbld/5'>near W279</scene>), at the top, via aromatic stacking interactions with conserved aromatic acid residues. E2020 does not, however, interact directly with either the catalytic triad or the 'oxyanion hole' but only <scene name='1eve/E20_interactionshown/8'>indirectly via solvent molecules</scene>.


== Relevance ==
==Conclusions==
The X-ray structure shows, a posteriori, that the design of E2020 took advantage of several important features of the active-site gorge of AChE, to produce a drug with both high affinity for AChE and a high degree of selectivity for AChE versus butyrylcholinesterase (BChE). It also delineates voids within the gorge that are not occupied by E2020 and could provide sites for potential modification of E2020 to produce drugs with improved pharmacological profiles.


== Structural highlights ==
==About this Structure==


This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
1EVE is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Torpedo_californica Torpedo californica]. The June 2004 RCSB PDB [http://pdb.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/index.html Molecule of the Month] feature on ''Acetylcholinesterase'' by David S. Goodsell is [http://dx.doi.org/10.2210/rcsb_pdb/mom_2004_6 10.2210/rcsb_pdb/mom_2004_6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EVE OCA].  


==Additional Resources==
For additional information, see: [[Alzheimer's Disease]]<br />
<br />
</StructureSection>
</StructureSection>
== References ==
 
<references/>
==Reference==
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307.  PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10368299 10368299]
 
[[ar:Aricept_Complexed_with_Acetylcholinesterase (Arabic)]]
[[ca:Aricept_Complexed_with_Acetylcholinesterase (Catalan)]]
[[zh:Aricept_Complexed_with_Acetylcholinesterase (Chinese)]]
[[cs:Aricept_Complexed_with_Acetylcholinesterase (Czech)]]
[[de:Aricept_Complexed_with_Acetylcholinesterase (German)]]
[[en:Aricept_Complexed_with_Acetylcholinesterase]]
[[es:Aricept_Complexed_with_Acetylcholinesterase (Spanish)]]
[[fr:Aricept_Complexed_with_Acetylcholinesterase (French)]]
[[he:Aricept_Complexed_with_Acetylcholinesterase (Hebrew)]]
[[it:Aricept_Complexed_with_Acetylcholinesterase (Italian)]]
[[ru:Aricept_Complexed_with_Acetylcholinesterase (Russian)]]
[[sk:Aricept_Complexed_with_Acetylcholinesterase (Slovak)]]
[[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]]
[[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]]
[[hi:Aricept Complexed with_Acetylcholinesterase (Hindi)]]<br />
 
[[Category: Acetylcholinesterase]]
[[Category: Single protein]]
[[Category: Torpedo californica]]
[[Category: Kryger, G.]]
[[Category: Silman, I.]]
[[Category: Sussman, J.L.]]
[[Category: E20]]
[[Category: NAG]]
[[Category: alpha/beta hydrolase]]
[[Category: alzheimer's disease]]
[[Category: catalytic triad]]
[[Category: drug]]
[[Category: glycosylated protein]]
[[Category: neurotransmitter cleavage]]
[[Category: serine hydrolase]]
[[Category: RCSB PDB Molecule of the Month]]

Revision as of 14:32, 20 January 2022


3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase

(see also AChE inhibitors and substrates)

Background

Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. E2020, marketed as Aricept, is a member of a large family of N-benzylpiperidine-based acetylcholinesterase (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of Torpedo californica AChE (TcAChE) (1ea5). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range.

Results

The X-ray structure of the E2020-TcAChE complex shows that E2020 has a along the active-site gorge, extending from the anionic subsite () of the active site, at the bottom, to the peripheral anionic site (), at the top, via aromatic stacking interactions with conserved aromatic acid residues. E2020 does not, however, interact directly with either the catalytic triad or the 'oxyanion hole' but only .

Conclusions

The X-ray structure shows, a posteriori, that the design of E2020 took advantage of several important features of the active-site gorge of AChE, to produce a drug with both high affinity for AChE and a high degree of selectivity for AChE versus butyrylcholinesterase (BChE). It also delineates voids within the gorge that are not occupied by E2020 and could provide sites for potential modification of E2020 to produce drugs with improved pharmacological profiles.

About this Structure

1EVE is a 1 chain structure with sequence from Torpedo californica. The June 2004 RCSB PDB Molecule of the Month feature on Acetylcholinesterase by David S. Goodsell is 10.2210/rcsb_pdb/mom_2004_6. Full crystallographic information is available from OCA.

Additional Resources

For additional information, see: Alzheimer's Disease


PDB ID 1eve

Drag the structure with the mouse to rotate

ReferenceReference

Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:10368299

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Joel L. Sussman